C11 BODIPY 581/591
目录号 : GC40165C11-BODIPY581/591是一种氧化敏感的荧光脂肪酸类似物,其荧光特性在可见光谱的红色范围内(发射峰值595nm),使其适用于荧光显微镜。
Cas No.:217075-36-0
Sample solution is provided at 25 µL, 10mM.
- Brain Res Bull 174 (2021): 250-259.PMID:34171402
- Acta Pharm Sin B 12.2 (2022): 692-707.PMID:35256940
- J Leukocyte Biol 110.2 (2021): 301-314.PMID:34318944
- Anal Chem 93.34 (2021): 11758-11764.PMID:34410685
- ACS Appl Mater Inter 13.45 (2021): 53671.PMID:34730938
- Front Mol Biosci 8 (2021): 725274.PMID:34568428
- Oxid Med Cell Longev 2021 (2021).PMID:34970416
- Eur J Pharmacol 919 (2022): 174797.PMID:35122867
- ACS nano 16.3 (2022): 3647-3663.PMID:35266697
- Transl Cancer Res 11.5 (2022): 1173.PMID:35706810
- J Nanobiotechnol 20.1 (2022): 230.PMID:35568865
- Chin Med-UK 17.1 (2022): 82.PMID:35787281
- Biomed Pharmacother 154 (2022): 113572.PMID:35988428
- Biochem Bioph Res Co 627 (2022): 103-110.PMID:36030651
- Life Sci 308 (2022): 120925.PMID:36057399
- Ebiomedicine 84 (2022).PMID:36137413
- Plos one 17.11 (2022): e0276083.PMID:36355759
- Cells 11.22 (2022): 3580.PMID:36429010
- Eur J Pharm Sci 181 (2023): 106350..PMID:36496165
- Redox Biol 59 (2023): 102564.PMID:36473315
- Cancer Lett 554 (2023): 216033.PMID:36493901
- Sci Total Environ 855 (2023): 158715.PMID:36113792
- J Exp Clin Canc Res 42.1 (2023): 1-19.PMID:36604718
- Chem Eng J 454 (2023): 140044.
- Free Radical Bio Med 195 (2023): 329-342.PMID:36610561
- Molecules 28.8 (2023): 3389.PMID:37110625
- Chem Eng J 466 (2023): 143012.
- Free Radical Bio Med 204 (2023): 226-242.PMID:37146698
- Acta Biomater (2023).PMID:37156432
- Chem Res Chinese U (2023): 1-6.
- Biochem Pharmacol 213 (2023): 115592.PMID:37196680
- J Nanobiotechnol 21.1 (2023): 1-19.PMID:37316835
- Int J Mol Med 52.5 (2023): 1-14.PMID:37800609
- Biochem Cell Biol 100.5 (2022): 378-386.PMID:35785548
- Cell Death Discov 8.1 (2022): 431.PMID:36307402
- Eur J Neurosci 58.1 (2023): 2194-2214.PMID:37161649
- Front Cell Neurosci 16 (2022): 774297.PMID:35431808
- Front Mol Biosci 9 (2022): 860525.PMID:35860356
- Front Oncol 11 (2022): 802124.PMID:35127512
- J Nanobiotechnol 20.1 (2022): 1-15.PMID:36109814
- J Biochem Mol Toxic (2023): e23542.PMID:37712196
- Method Protocol (2023): 165-178.PMID:37578705
- Eur J Neurosci 58.1 (2023): 2194-2214.PMID:37161649
- Exp Ther Med 26.5 (2023): 1-15.PMID:37869642
- J Pharm Anal (2023).
- The Prostate (2023).PMID:37750290
- Int Immunopharmacol 127 (2024):111377.PMID:38104369
- Redox Rep 29.1 (2024):2290864.PMID:38149613
- Bioact Mater 33 (2024):483-496.PMID:38125638
- Biochem Bioph Res Co 690 (2024):149274.PMID:37995455
- J Mater Chem B (2024).PMID:38063821
- Biol Trace Elem Res (2024):1-11.PMID:38183555
- J Orthop Transl 44 (2024):114-124.
- J Mol Struct (2024):137668.
- Cell Signal (2024):111108.PMID:38369266
- J Funct Foods 113 (2024):106018.
- Kaohsiung J Med Sci (2024).PMID:38340032
- Pharm Biol 62.1 (2024):195-206.PMID:38339810
- Research (2024).PMID:38371274
- Cell Death Differ (2024):1-16.PMID:38418695
- Carcinogenesis (2024):bgae016.PMID:38422369
- Int J Biol Sci 20.5 (2024):1707.PMID:38481805
- bioRxiv (2024):2024-03.
- Sci Total Environ (2024):171818.PMID:38508245
- Appl Organomet Chem (2024):e7456.
- Heliyon (2024).
- Antioxid Redox Sign (2024).PMID:38545792
- Biomed Pharmacother 174 (2024):116542.PMID:38574620
- Bone Res 12.1 (2024):20.PMID:38553442
- Cancer Lett (2024):216826.PMID:38574881
- Heliyon (2024).PMID:38576562
- Free Radical Bio Med (2024).PMID:38614226
- Bmc Cancer 24.1 (2024):1-15.PMID:38637761
- Antioxid Redox Sign (2024).PMID:38545792
- Bmc Cancer 24.1 (2024):496.PMID:38637761
- Int Immunopharmacol 134 (2024):112177.PMID:38696908
- J Cell Mol Med 28.8 (2024):e18335.PMID:38652216
- J Exp Clin Canc Res 43.1 (2024):1-20.PMID:38745179
- J Ethnopharmacol (2024):118363.PMID:38763373
- Biomacromolecules (2024).PMID:38779908
- Mol Cancer 23.1 (2024):113.PMID:38802795
- Nat Commun 15.1 (2024):4760.PMID:38834654
- Biochem Pharmacol (2024):116345.PMID:38852643
- Heliyon (2024).
- Environ Res (2024):119483.PMID:38914254
- J Nanobiotechnol 22.1 (2024):353.PMID:38902759
- Sci Rep-Uk 14.1 (2024):15246.PMID:38956068
- J Nanobiotechnol 22.1 (2024):390.PMID:38961442
- Sci Total Environ (2024):174532.PMID:38972417
- Free Radical Bio Med (2024).PMID:38996820
- Int J Biol Macromol (2024):134149.
- Nutrients 16.14 (2024):2314.
- Clin Transl Oncol (2024):1-13.PMID:39060774
- Front Pharmacol 15 (2024):1440147.PMID:37059385
- J Control Release 373 (2024):599-616.PMID:39074587
- Cell Death Dis 15.8 (2024):611.PMID:39174525
- Chem Eng J (2024):155019.
- Mol Med 30.1 (2024):1-18.PMID:39266965
- Cell Death Dis 15.8 (2024):611.PMID:39174525
- Arch Med Sci (2024).
- Npj Biofilms Microbi 10.1 (2024):102.PMID:39370453
- Adv Sci (2024):2406343.PMID:39420512
- Biol Direct 19.1 (2024):1-16.PMID:39438996
-
Related Biological Data
Intracellular ferroptosis evaluations. d) CLSM images of C11-BODIPY581/591-stained 4T1 cells after CMS treatment (scale bar = 20 μm).
C11-BODIPY581/591 was purchased from GLPBIO.
Bioactive Materials, 2024, 33: 483-496. PMID: 38125638 IF: 18.8997 -
Related Biological Data
GSS contributes to GBM cell resistance to radiotherapy-induced ferroptosis. (J) Confocal microscopy visualized the alterationsin lipid peroxidation in LN229 cells after C11-BODIPY probe staining.
The C11 BODIPY 581/591 assay kit (GLPBIO, USA, GC40165) was used following the manufacturer’s manual.
ACS nano, 2023. PMID: 37646615 IF: 17.0997 -
Related Biological Data
Mechanisms of action studies of RF@LA-Fe-MOF. (b) LPO levels in C5WN1 cells after incubated with RF@LA-Fe-MOF (5 or 10μg mL-1) for 12 h.
Cells were stained with C11-BODIPY581/591 (5 × 10-6 M) (GlpBio, USA)for 10 min in PBS (pH 7.4) solution and imaged by CLSM.
Chem Eng J 454 (2023): 140044. IF: 16.7438 -
Related Biological Data
Ferroptosis-inducing ability of Cu2−XS-GOx@CaCO3. (E) LPO detection within treated cells.
Afterwards, the treated cells were stained with C11-BODIPY 581/591 (GlpBio Technology) and incubated for 30 min.
Chem Eng J (2023): 143012. IF: 16.7438 -
Related Biological Data
Mechanism of DFMC induced ferroptosis. (e) LPO level of CT26 cells incubated with DFMC.
Following the protocol of the product for the next steps, the media were replaced with the diluted C11-BODIPY581/591 (GlpBio, USA) staining solution, and incubated for 20 min.
ACS nano (2022). PMID: 35266697 IF: 15.8814 -
Related Biological Data
BPQDs cause ferroptosis in lung A549 cells. The lipid peroxidation level was measured with C11 BODIPY staining as detected using D) fluorescent images.
Briefly, cells were incubated in six-well plates with BPQDs for 24h, and then washed with cold phosphate buffer saline (PBS) three times and incubated with C11 BODIPY 581/591(GlpBio, USA) for 30 min at 37°C.
Small Methods (2021): 2001045. PMID: 3492782 IF: 14.18
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
本方案仅提供一个指导,请根据您的具体需要进行修改。
1.染色液的制备
(1)配置储存液:使用DMSO溶解C11 BODIPY 581/591,配置浓度为1-10mM的储存液。
注意:未使用的储存液分装后在-20℃或-80°C避光保存,避免反复冻融。
(2)配置工作液:用合适的缓冲液(如:无血清培养基或PBS)稀释储存液,配制浓度为1-10μM的工作液。
注意:请根据实际情况调整工作液浓度,现用现配。
2.细胞悬浮染色
(1)悬浮细胞:经4°C、1000g离心3-5分钟,弃去上清液,用PBS清洗两次,每次5分钟。
(2)贴壁细胞:使用PBS清洗两次,加入胰酶消化细胞,消化完成后经1000g离心3-5min。
(3)加入1mL的C11 BODIPY 581/591工作溶液重悬细胞,37 °C避光孵育5-30分钟。不同细胞最佳孵育时间不同,请根据具体实验需求自行摸索。
(4)孵育结束后,经1000g离心5分钟,去除上清液,加入PBS清洗2-3次,每次5分钟。
(5)用预温的无血清细胞培养基或PBS重悬细胞,通过荧光显微镜或流式细胞术观察。
3.细胞贴壁染色
(1)在无菌盖玻片上培养贴壁细胞。
(2)从培养基中移走盖玻片,吸出过量的培养基,将盖玻片放在潮湿的环境中。
(3)从盖玻片的一角加入100μL的染料工作液,轻轻晃动使染料均匀覆盖所有细胞。
(4) 37 °C避光孵育5-30分钟。不同细胞最佳孵育时间不同,请根据具体实验需求自行摸索。
(5)孵育结束后吸弃染料工作液,使用预温的培养液清洗盖玻片2~3次。
4.显微镜检测:C11 BODIPY 581/591氧化型的激发光和发射光分别为460-495nm和510-550nm;还原型的激发光和发射光分别为565-581nm和585-591nm。
注意事项:
1)荧光染料均存在淬灭问题,请尽量注意避光,以减缓荧光淬灭。
2)为了您的安全和健康,请穿实验服并戴一次性手套操作。
C11-BODIPY581/591 is an oxidation-sensitive fluorescent fatty acid analogue with fluorescent properties in the red range of the visible spectrum (emission maximum 595 nm), allowing its application in fluorescence microscopy. C11-BODIPY581/591 is easily incorporating into membranes and fluoresces red in the intact state but shifts to green upon free radical-induced oxidation. This characteristic is highly advantageous, it makes the ratio-imaging of oxidant activities at the (sub)cellular level feasible. In addition, the fluorescent properties of C11-BODIPY581/591 allow the use of this probe in fast- and medium- throughput screening of antioxidants in living cells and model membranes in a multiwell/fluorescence reader approach[1][2].
The wavelengths of maximal excitation and emission of fluorophore C11-BODIPY581/591 corresponded to 581 and 591 nm, respectively. Addition of CumOOH/hemin, as an initiator of lipid oxidation, shifted the excitation and emission spectra to shorter wavelengths corresponding to green fluorescence (peak excitation 500 nm, emission 510 nm). C11-BODIPY581/591 is also easily oxidized by other hydroxy-, peroxy- and oxy-radical generating systems such as hydrogen peroxide/Fe2+ and 2,2’-azobis. However, this probe is relatively insensitive to SIN-1, which generates nitric oxide and superoxide[3]
References:
[1]. Drummen GP, et al. C11-BODIPY581/591, an oxidation-sensitive fluorescent lipid peroxidation probe: (micro)spectroscopic characterization and validation of methodology. Free Radic Biol Med. 2002 Aug 15;33(4):473-90.
[2]. Partyka A, et al. Detection of lipid peroxidation in frozen-thawed avian spermatozoa using C11-BODIPY581/591. Theriogenology. 2011 Jun;75(9):1623-9.
[3]. Pap EH, et al. Ratio-fluorescence microscopy of lipid oxidation in living cells using C11-BODIPY581/591. FEBS Lett. 1999 Jun 25;453(3):278-82.
C11-BODIPY581/591是一种氧化敏感的荧光脂肪酸类似物,其荧光特性在可见光谱的红色范围内(发射峰值595nm),使其适用于荧光显微镜。 C11-BODIPY581/591容易被纳入膜中,在完整状态下呈现红色荧光,但在自由基诱导氧化时会转变为绿色。这个特点非常有优势,它使得可以在(亚)细胞水平上进行氧化剂活性比率成像。此外,C11-BODIPY581/591的荧光特性还可以利用多孔板/荧光读数器方法,在活体细胞和模型膜中快速筛选抗氧化剂[1][2]。
荧光染料C11-BODIPY的最大激发和发射波长分别为581和591纳米。添加脂质氧化引发剂CumOOH/hemin后,激发和发射光谱向短波长移动,对应着绿色荧光(峰值激发500纳米,发射510纳米)。C11-BODIPY还容易被其他羟基、过氧化物和氧自由基产生系统如双氧水/Fe2+ 和 2,2'-偶氮丙烷等氧化。然而,这种探针对于生成一氧化氮和超氧阴离子的SIN-1相对不敏感[3]。
Cas No. | 217075-36-0 | SDF | |
化学名 | (T-4)-difluoro[5-[[5-[(1E,3E)-4-phenyl-1,3-butadien-1-yl]-2H-pyrrol-2-ylidene-κN]methyl]-1H-pyrrole-2-undecanoato(2-)-κN1]-borate(1-), monohydrogen | ||
Canonical SMILES | [F-][B+3]1([N]2=C(/C=C/C=C/C3=CC=CC=C3)C=CC2=CC4=CC=C(CCCCCCCCCCC([O-])=O)[N-]14)[F-].[H+] | ||
分子式 | C30H34BF2N2O2 • H | 分子量 | 504.4 |
溶解度 | 30mg/ml in DMSO,Slightly soluble in Methanol | 储存条件 | Store at -20°C; protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.9826 mL | 9.9128 mL | 19.8255 mL |
5 mM | 0.3965 mL | 1.9826 mL | 3.9651 mL |
10 mM | 0.1983 mL | 0.9913 mL | 1.9826 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Ginsenoside Rg1 ameliorates sepsis-induced acute kidney injury by inhibiting ferroptosis in renal tubular epithelial cells
J Leukoc Biol 2022 Nov;112(5):1065-1077.PMID:35774015DOI:10.1002/JLB.1A0422-211R.
Acute kidney injury (AKI) represents a prevailing complication of sepsis, and its onset involves ferroptosis. Ginsenoside Rg1 exerts a positive effect on kidney diseases. This study explored the action of ginsenoside Rg1 in sepsis-induced AKI (SI-AKI) by regulating ferroptosis in renal tubular epithelial cells (TECs). Sepsis rat models were established using cecal ligation and puncture (CLP) and cell models were established by treating human renal TECs (HK-2) with LPS to induce ferroptosis. Serum creatinine (SCr) and blood urea nitrogen (BUN) and urine KIM1 contents in rats were determined by ELISA kits. Kidney tissues were subjected to immunohistochemical and H&E stainings. Iron concentration, malondialdehyde (MDA), glutathione (GSH), and ferroptosis-related protein (ferritin light chain [FTL], ferritin heavy chain [FTH], GSH peroxidase 4 [GPX4], and Ferroptosis suppressor protein 1 [FSP1]) levels in kidney tissues and HK-2 cells were measured using ELISA kits and Western blotting. HK-2 cell viability was detected by cell counting kit-8, and cell death was observed via propidium iodide staining. Reactive oxygen species accumulation in cells was detected using C11 BODIPY 581/591 as a molecular probe. In CLP rats, ginsenoside Rg1 reduced SCr, BUN, KIM1, and NGAL levels, thus palliating SI-AKI. Additionally, ginsenoside Rg1 decreased iron content, FTL, FTH, and MDA levels, and elevated GPX4, FSP1, and GSH levels, thereby inhibiting lipid peroxidation and ferroptosis. Moreover, FSP1 knockdown annulled the inhibition of ginsenoside Rg1 on ferroptosis. In vitro experiments, ginsenoside Rg1 raised HK-2 cell viability and lowered iron accumulation and lipid peroxidation during ferroptosis, and its antiferroptosis activity was dependent on FSP1. Ginsenoside Rg1 alleviates SI-AKI, possibly resulting from inhibition of ferroptosis in renal TECs through FSP1.
Tirapazamine suppress osteosarcoma cells in part through SLC7A11 mediated ferroptosis
Biochem Biophys Res Commun 2021 Aug 27;567:118-124.PMID:34147710DOI:10.1016/j.bbrc.2021.06.036.
Osteosarcoma is the most common primary orthopedic malignant bone tumor in adolescents. However, the traditional neoadjuvant chemotherapy regimen has reached the bottleneck. TPZ is a hypoxic prodrug that has a powerful anti-tumor effect in the hypoxic microenvironment of tumors. And ferroptosis is a newly discovered cell death in 2012, and ferroptosis inducers have been used in anti-tumor therapy research in recent decades. Though, the role of TPZ and ferroptosis in osteosarcoma remains unclear. The aim of this study was to investigate the role of TPZ in osteosarcoma and the specific mechanism. MTT assay showed the extraordinary inhibition of TPZ on three osteosarcoma cells under hypoxia. And fluorescence of Fe2+ staining was enhanced by TPZ. Western blotting showed decreased expression of SLC7A11 and GPX4. Lipid peroxidation was confirmed by MDA assay and C11 BODIPY 581/591 staining. SLC7A11 overexpression could restored the proliferation and migration abilities inhibited by TPZ. Thus, we for the first time demonstrated that TPZ could inhibit the proliferation and migration of osteosarcoma cells, and induce ferroptosis in part through inhibiting SLC7A11.
[Carbenoxolone enhances inhibitory effect of RSL3 against cisplatin-resistant testicular cancer cells by promoting ferroptosis]
Nan Fang Yi Ke Da Xue Xue Bao 2022 Mar 20;42(3):405-410.PMID:35426805DOI:10.12122/j.issn.1673-4254.2022.03.13.
Objective: To investigate the inhibitory effect of RSL3 on the proliferation, invasion and migration of cisplatinresistant testicular cancer cells (I-10/DDP) and the effect of carbenoxolone on the activity of RSL3 against testicular cancer. Methods: MTT assay was used to evaluate the survival rate of I-10/DDP cells following treatment with RSL3 (1, 2, 4, 8, 16 or 32 μmol/L) alone or in combination with carbenoxolone (100 μmol/L) or after treatment with Fer-1 (2 μmol/L), RSL3 (4 μmol/L), RSL3+Fer-1, RSL3+carbenoxolone (100 μmol/L), or RSL3+Fer-1+carbenoxolone. Colony formation assay was used to assess the proliferation ability of the treated cells; wounding-healing assay and Transwell assay were used to assess the invasion and migration ability of the cells. The expression of GPX4 was detected using Western blotting, the levels of lipid ROS were detected using C11 BODIPY 581/591 fluorescent probe, and the levels of Fe2+ were determined with FerroOrange fluorescent probe. Results: RSL3 dose-dependently decreased the survival rate of I-10/DDP cells, and the combined treatment with 2, 4, or 8 μmol/L RSL3 with carbenoxolone, as compared with RSL3 treatment alone, resulted in significant reduction of the cell survival rate. The combination with carbenoxolone significantly enhanced the inhibitory effect of RSL3 on colony formation, wound healing rate (P=0.005), invasion and migration of the cells (P < 0.001). Fer-1 obviously attenuated the inhibitory effects of RSL3 alone and its combination with carbenoxolone on I-10/DDP cells (P < 0.01). RSL3 treatment significantly decreased GPX4 expression (P=0.001) and increased lipid ROS level (P=0.001) and Fe2+ level in the cells, and these effects were further enhanced by the combined treatment with carbenoxolone (P < 0.01). Conclusion: Carbenoxolone enhances the inhibitory effect of RSL3 on the proliferation, invasion and migration of cisplatin-resistant testicular cancer cells by promoting RSL3-induced ferroptosis.
Hyperbaric oxygen protects HT22 cells and PC12 cells from damage caused by oxygen-glucose deprivation/reperfusion via the inhibition of Nrf2/System Xc-/GPX4 axis-mediated ferroptosis
PLoS One 2022 Nov 10;17(11):e0276083.PMID:36355759DOI:10.1371/journal.pone.0276083.
This study was to investigate the protective effect of hyperbaric oxygen (HBO) on HT22 and PC12 cell damage caused by oxygen-glucose deprivation/reperfusion-induced ferroptosis. A 2-h oxygen-glucose deprivation and 24-h reperfusion model on HT22 and PC12 cells was used to simulate cerebral ischemia-reperfusion injury. Cell viabilities were detected by Cell Counting Kit-8 (CCK-8) method. The levels of reactive oxygen species (ROS) and lipid reactive oxygen species (Lipid ROS) were detected by fluorescent probes Dihydroethidium (DHE) and C11 BODIPY 581/591. Iron Colorimetric Assay Kit, malondialdehyde (MDA) and glutathione (GSH) activity assay kits were used to detect intracellular iron ion, MDA and GSHcontent. Cell ferroptosis-related ultrastructures were visualized using transmission electron microscopy (TEM). Furthermore, PCR and Western blot analyses were used to detect the expressions of ferroptosis-related genes and proteins. After receiving oxygen-glucose deprivation/reperfusion, the viabilities of HT22 and PC12 cells were significantly decreased; ROS, Lipid ROS, iron ions and MDA accumulation occurred in the cells; GSH contents decreased; TEM showed that cells were ruptured and blebbed, mitochondria atrophied and became smaller, mitochondrial ridges were reduced or even disappeared, and apoptotic bodies appeared. And the expressions of Nrf2, SLC7A11 and GPX4 genes were reduced; the expressions of p-Nrf2/Nrf2, xCT and GPX4 proteins were reduced. Notably, these parameters were significantly reversed by HBO, indicating that HBO can protect HT22 cells and PC12 cells from damage caused by oxygen-glucosedeprivation/reperfusion via the inhibition of Nrf2/System Xc-/GPX4 axis-mediated ferroptosis.
Cinnamtannin B-1, a novel antioxidant for sperm in red deer
Anim Reprod Sci 2018 Aug;195:44-52.PMID:29776697DOI:10.1016/j.anireprosci.2018.05.004.
Cinnamtannin B-1 (CNB-1) is a naturally occurring trimeric A-type proanthocyanidin contained in several plants such as cinnamon (Cinnamomum zeylanicum). It is considered to be a potent antioxidant. The protective effect of CNB-1 against oxidative stress was assessed in red deer epididymal sperm incubated at 37 °C. Cryopreserved sperm from six stags were thawed, pooled and extended to 400 × 106 sperm/ml in BGM (bovine gamete medium). After being aliquoted, the samples were supplemented with different concentrations of CNB-1 (0, 0.1, 1, 10 and 100 μg/mL), with or without induced oxidative stress (100 μM Fe2+/ascorbate). The samples were evaluated after 0, 2 and 4 h of incubation at 37 °C. This experiment was replicated six times. Spermmotility (CASA), viability, mitochondrial membrane potential, acrosomal status, lipoperoxidation (C11 BODIPY 581/591), intracellular reactive oxygen species (ROS) production and DNA status (TUNEL) were assessed. After 4 h of incubation, CNB-1 prevented the deleterious effects of oxidative stress, thus improved sperm progressivity and velocity (P<0.05). Furthermore, 1 and 10 μM CNB-1 improved sperm linearity, even when compared to those samples that had not been subjected to oxidative stress (P<0.05). The greatest concentration, 100 μM, prevented sperm lipoperoxidation and reduced ROS production in samples subjected to oxidative stress.